What's Happening?
The Alzheimer's Drug Discovery Foundation (ADDF) has announced the retirement of its Co-Founder and Chief Science Officer, Dr. Howard Fillit, who will transition to an emeritus role. Dr. Fillit has been instrumental in guiding the ADDF's scientific vision
for over three decades, contributing significantly to advancements in Alzheimer's research. The foundation is now searching for a new Chief Science Officer to continue its mission of accelerating drug development for Alzheimer's disease. Dr. Laura Nisenbaum will serve as Interim CSO during the search process.
Why It's Important?
Dr. Fillit's retirement marks the end of an era for the ADDF, which has been at the forefront of Alzheimer's research and drug development. Under his leadership, the foundation has pioneered a precision medicine approach, moving beyond a singular focus on amyloid to encompass the full pathobiology of Alzheimer's. This broader approach has been crucial in developing new diagnostic tools and therapies, significantly impacting the field. The search for a new CSO is critical as the ADDF continues to drive innovation and collaboration in Alzheimer's research, aiming to deliver new treatments to patients.
What's Next?
The ADDF will work with Russell Reynolds Associates to identify a new Chief Science Officer who can build on Dr. Fillit's legacy and guide the foundation's scientific strategy. The new CSO will play a pivotal role in shaping the next era of Alzheimer's research, focusing on high-impact projects and collaborations. The foundation's ongoing commitment to funding innovative research will continue to be a driving force in the development of new therapies and diagnostic tools for Alzheimer's disease.
